01 Industry overview
The medical AI industry at a glance
Medical AI is entering a scaling phase: global revenue is estimated at $56.2 billion in 2026, while healthcare AI spending reached $3.7 billion and U.S. FDA-authorized AI devices exceeded 1,600.
- $56.2B[3]
- Medical AI market, 2026
- 34.0%[3]
- Forecast CAGR, 2026–2036
- 1,356[16]
- FDA-authorized devices, 2025
- 85%[17]
- Physicians using AI weekly, 2026
- Market size
- The global medical AI market was valued at $42.6 billion in 2025 and is estimated at $56.2 billion in 2026. The estimate covers applications including patient engagement, digital pathology, genomic diagnostics and multimodal diagnostics.[3]
- Forecast & CAGR
- Grand View Research projects the market to reach $1,050.6 billion by 2036, implying a 34.0% CAGR from 2026 to 2036. Growth is attributed to demand for minimally invasive procedures, real-time monitoring, personalized care and AI-supported drug development.[3]
- Market share & regions
- North America held 44.0% of global medical AI revenue in 2025, making it the largest regional market. Asia Pacific was identified as the fastest-growing region for 2026–2036, while the United States held the largest country share in 2025.[3]
- Segmentation
- Healthcare providers represented 63.6% of the market by end use in 2025. Treatment and intervention accounted for 28.3% by patient journey, while patient engagement was the largest application at 21.0%.[3]
- Key players & concentration
- By December 2025, the FDA had authorized 1,356 AI/ML-enabled medical devices from 693 companies. GE Healthcare led with 93 devices and Siemens Healthineers followed with 82, while most of the 626 companies with at least one authorization held only one or two devices, indicating a concentrated top tier within a fragmented market.[16]
- Trends, drivers & challenges
- Medical AI is expanding from imaging into clinical copilots, ambient documentation, patient engagement and drug discovery. Key challenges include clinical validation, monitoring model changes, data privacy and the gap between regulatory authorization and real-world clinical adoption; only 2.4% of devices with clinical studies were supported by randomized-trial data through 2024.[18][16][19]
- Consumer behavior & competition
- In Doximity's 2026 report, 85% of 3,379 U.S. physicians said they used AI professionally at least weekly, up from 51% in 2025. Competition is shifting toward workflow integration: Menlo Ventures reported that Microsoft and Epic captured 68% of new ambient-scribing spend in 2026.[17][18]
- M&A
- Healthcare and pharmaceutical information-technology M&A totaled 392 transactions worth $31 billion in 2025, up 11% in volume and 72% in value from 2024. Siemens' $5.1 billion acquisition of Dotmatics was the largest transaction tracked in the sector during 2025, although the report covers healthcare IT broadly rather than medical AI alone.[20]
- Regulation
- The FDA regulates AI-enabled medical devices under the Federal Food, Drug, and Cosmetic Act using risk-based pathways including 510(k), De Novo and premarket approval. The agency reported more than 1,600 AI-enabled medical devices authorized for U.S. marketing as of September 2026 and supports predetermined change-control plans for certain software updates.[5]
- Latest news
- Menlo Ventures reported that healthcare AI spending grew 2.5 times to $3.7 billion in 2026. Within that total, drug-discovery spending rose from $30 million to $700 million, clinical-copilot spending reached $550 million and patient-engagement spending reached $450 million.[18]
02 Ranking
Top 10 Companies in the Medical AI Industry
The leading companies in the medical AI industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 20, 2026 · Next review December 20, 2026
Shanghai United Imaging Healthcare stands out for medical imaging, radiotherapy and healthcare AI because United Imaging had more than 20 FDA-cleared AI-enabled products at the end of 2025, while Viz.ai focuses on disease detection and intelligent care coordination since it reported adoption in nearly 2,000 hospitals across the United States at the end of 2025.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in medical imaging platforms
Shanghai United Imaging Healthcare
CN
Ranked #1 · 9.3 · Medical imaging platforms
Why we picked it: It offers medical imaging, radiotherapy and healthcare AI, supported by revenue growth of 33.98% and R&D at 18.99% of revenue.
Leader in clinical care coordination
Viz.ai
US
Ranked #2 · 9.0 · Clinical care coordination
Why we picked it: It focuses on disease detection and intelligent care coordination, reporting revenue growth of 73.9%.
Leader in clinical imaging AI
Aidoc
IL
Ranked #4 · 9.0 · Clinical imaging AI
Why we picked it: It concentrates on clinical imaging AI and care coordination at hospital scale and high annual patient volumes.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Shanghai United Imaging Healthcare Medical imaging platforms · CN | 9.3 | 9.2 | 9.9 | 9.6 | 9.4 | |
Company snapshot · Shanghai United Imaging Healthcare · Data as of November 20, 2026 United Imaging had more than 20 FDA-cleared AI-enabled products at the end of 2025.[21]
| |||||||
| 2 | Viz.ai Clinical care coordination · US | 9.0 | 8.4 | 9.9 | 9.6 | 9.1 | |
Company snapshot · Viz.ai · Data as of November 20, 2026 Viz.ai reported adoption in nearly 2,000 hospitals across the United States at the end of 2025.[22]
| |||||||
| 3 | Siemens Healthineers Medical imaging platforms · DE | 9.0 | 9.8 | 7.7 | 8.5 | 9.1 | |
Company snapshot · Siemens Healthineers · Data as of November 20, 2026 Siemens Healthineers ranked second in FDA-authorized AI medical devices with 82 through 2025.[16]
| |||||||
| 4 | Aidoc Clinical imaging AI · IL | 9.0 | 8.4 | 9.0 | 9.4 | 9.1 | |
Company snapshot · Aidoc · Data as of November 20, 2026 Aidoc says its clinical AI is used in more than 1,600 hospitals and analyzes 60 million patients annually.[23]
| |||||||
| 5 | Tempus AI Precision-medicine data AI · US | 8.9 | 8.4 | 8.1 | 9.9 | 9.9 | |
Company snapshot · Tempus AI · Data as of November 20, 2026 Tempus uses AI with clinical and molecular data to support precision-medicine decisions.[24]
| |||||||
| 6 | SOPHiA GENETICS Genomic and multimodal clinical AI · CH | 8.7 | 8.4 | 7.7 | 9.0 | 9.4 | |
Company snapshot · SOPHiA GENETICS · Data as of November 20, 2026 SOPHiA GENETICS provides AI-driven genomic analysis for clinical and research workflows.[25]
| |||||||
| 7 | Clarius Mobile Health AI-enabled wireless ultrasound · CA | 8.5 | 7.0 | 9.3 | 9.4 | 9.1 | |
Company snapshot · Clarius Mobile Health · Data as of November 20, 2026 Clarius Mobile Health is listed among major companies in the AI and machine-learning medical-device market.[26]
| |||||||
| 8 | Butterfly Network AI-native point-of-care ultrasound · US | 8.5 | 8.4 | 7.7 | 8.7 | 9.1 | |
Company snapshot · Butterfly Network · Data as of November 20, 2026 Butterfly combines semiconductor ultrasound devices, software and AI for point-of-care imaging.[27]
| |||||||
| 9 | Medtronic AI-enabled surgery and medical devices · IE | 8.5 | 8.4 | 7.9 | 8.9 | 7.4 | |
Company snapshot · Medtronic · Data as of November 20, 2026 Medtronic launched AI-driven surgical performance insights algorithms for laparoscopic and robotic procedures.[26]
| |||||||
| 10 | iRhythm Technologies AI-enabled ambulatory cardiac monitoring · US | 8.4 | 7.6 | 8.1 | 9.2 | 8.1 | |
Company snapshot · iRhythm Technologies · Data as of November 20, 2026 iRhythm is identified as a specialist vendor in regulated AI medical software and clinical monitoring.[25]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 20, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 20). Top 10 companies in the medical AI industry. In Medical AI Industry Statistics. Gitnux. https://gitnux.org/medical-ai-industry-statistics/#top-companies
AI-enabled medical devices on the FDA list, by final decision year (United States)
AI-enabled medical devices on the FDA list, by final decision year grew from 114 in 2020 to 335 in 2025.
03 Trends & forecasts
Top 10 Medical AI Industry Trends & Forecasts 2027
What is changing in the medical AI industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Medical AI revenue accelerates sharply
High confidenceGrand View Research estimates the global medical AI market at $56.2 billion in 2026, up from $42.6 billion in 2025, with a projected 34.0% CAGR through 2036. North America represented 44.0% of 2025 revenue, while Asia Pacific was the fastest-growing region in the forecast period.[3]
Forecast 2027: Global medical AI revenue should continue expanding rapidly in 2027, supported by provider deployment, clinical software adoption and AI-enabled drug development. Growth is likely to remain above 30% year over year, although realized revenue will trail the most aggressive long-term market forecasts.
02Physician AI adoption becomes mainstream
High confidenceThe American Medical Association reported that 81% of physicians used AI professionally in 2026, compared with 38% in 2023. The most common use cases included research summaries, clinical documentation, chart summaries and patient communications.[19]
Forecast 2027: In 2027, AI use should shift from experimentation to routine workflow participation, particularly for documentation, information retrieval and communication. Adoption will increase fastest where tools are embedded in existing clinical systems and retain clinician review.
03Clinical copilots move toward patient care
High confidenceMenlo Ventures reported that clinical-copilot spending grew 5.5 times to $550 million in 2026. Healthcare AI spending overall reached $3.7 billion, growing 2.5 times year over year, as investment moved beyond back-office automation.[18]
Forecast 2027: Clinical copilots should be one of the fastest-growing medical AI categories in 2027, expanding from evidence retrieval and note support into care planning, follow-up and decision preparation. Vendors will compete on accuracy, auditability and integration rather than on general-purpose chatbot features alone.
04Ambient scribes consolidate around incumbents
High confidenceMenlo Ventures found that Microsoft and Epic captured 68% of new ambient-scribing spend in 2026. It also reported that every major EHR offered a built-in scribe and that basic note-taking had become increasingly commoditized.[18]
Forecast 2027: In 2027, ambient documentation will increasingly be bundled with EHR, productivity and revenue-cycle platforms. Independent vendors will need to differentiate through specialty workflows, measurable documentation quality, international language support or broader clinical-assistant capabilities.
05Drug-discovery AI enters clinical testing
High confidenceMenlo Ventures reported that AI drug-discovery spending rose from $30 million to $700 million in 2026. A 2026 analysis identified 129 AI-enabled therapeutic assets across 69 companies that had entered human clinical trials by March 1, 2026, although only five had reached Phase 3.[18][28]
Forecast 2027: Drug-discovery AI investment should remain strong in 2027, with more programs entering Phase 1 and Phase 2 trials. Commercial proof will remain limited because most programs are early-stage, making clinical success rates and regulatory progress more important than model benchmarks.
06Patient-engagement AI expands rapidly
High confidenceMenlo Ventures reported that patient-engagement spending grew 4.5 times to $450 million in 2026. Grand View Research identified patient engagement as the largest medical AI application segment, with a 21.0% share of 2025 revenue.[18][3]
Forecast 2027: Patient-facing AI should expand in 2027 through triage, education, scheduling, adherence and portal communication. Providers will favor systems that are tightly bounded, disclose uncertainty and escalate appropriately to human staff.
07Payers adopt AI more cautiously
High confidenceMenlo Ventures estimated that external payer AI spending was only $150 million in 2026, about 19 times lower than provider spending. Nevertheless, 82% of payers identified prior authorization as their top AI priority, up from 59% previously.[18]
Forecast 2027: Payer AI deployment should accelerate in 2027, led by prior authorization, utilization management, claims operations and fraud detection. Regulatory scrutiny and concerns about denial explainability will constrain autonomous decisions and favor human-review models.
08FDA authorizations continue climbing
High confidenceThe FDA reported more than 1,600 AI-enabled medical devices authorized for U.S. marketing as of September 2026. The agency uses risk-based pathways including 510(k), De Novo and premarket approval, and allows predetermined change-control plans for certain software updates.[5]
Forecast 2027: The authorized-device base should exceed 1,800 in 2027 if the recent pace continues, with imaging remaining a major source of new clearances. Regulatory differentiation will increasingly focus on post-market monitoring, software changes and evidence for real-world performance.
09Generative-device regulation becomes clearer
Medium confidenceIn 2026, the FDA sought public feedback on a regulatory approach for generative-AI-enabled medical devices. Its current framework evaluates intended use and technological characteristics and can review significant software modifications.[5]
Forecast 2027: In 2027, developers should face more explicit expectations for model updates, human oversight, transparency and performance monitoring. Clearer guidance may reduce regulatory uncertainty, but it will also raise compliance costs for generative systems used in diagnosis or treatment.
10Clinical evidence becomes a competitive moat
High confidenceThe reviewed industry overview reports that only 2.4% of AI-enabled devices with clinical studies through 2024 were supported by randomized-trial data. The 2026 AI-drug-discovery pipeline analysis likewise found that most assets remained early-stage, with only five of 129 identified assets reaching Phase 3.[28][5]
Forecast 2027: In 2027, health systems and regulators should place greater weight on prospective validation, subgroup performance and post-deployment monitoring. Vendors with randomized or pragmatic evidence will gain an advantage in procurement, reimbursement and clinical trust.
04 Statistics
Market Intelligence
This section anchors market sizing and authorization scale, including $56.20 billion in 2026 and more than 1,600 AI-enabled devices with FDA marketing authorization as of September 2026.
Market size and revenue in the medical AI industry
- $5.98 billion was the U.S. artificial-intelligence-in-healthcare market in 2024, covering integrated offerings across diagnosis, genomics, precision medicine, radiation, telehealth, immunotherapy, pharmacy and supply-chain functions.[1]
- $11.5 billion was the global medical AI market in 2024, covering products, applications and sales channels across North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.[2]
- $42.62 billion was the global medical AI market in 2025, covering patient engagement, digital pathology, genomic diagnostics and multimodal diagnostics AI across applications, end uses, patient journeys and regions.[3]
Growth forecasts for the medical AI industry
- The global AI-in-healthcare market is projected to reach $188.4 billion in 2030 from $26.7 billion in 2024, implying a 38.5% CAGR for 2024–2030.[4]
- The global medical AI market is projected to reach $1,050.63 billion in 2036 from $56.20 billion in 2026, implying a 34.0% CAGR for 2026–2036.[3]
- The U.S. AI-in-healthcare market is projected to reach $43.30 billion in 2030 from $8.65 billion in 2025, implying a 38.0% CAGR for 2025–2030.[1]
Product counts and provider structure in the medical AI industry
- More than 150 AI/ML-enabled medical devices were authorized in the United States during 2024, according to the FDA's CDRH annual report.[5]
- 1,430 FDA-authorized AI/ML-enabled medical devices were recorded from September 1995 through December 2025, spanning 576 unique manufacturers in the United States.[6]
- More than 1,600 AI-enabled medical devices had FDA marketing authorization in the United States as of September 2026, covering the agency's identified AI-enabled medical-device list.[5]
05 Statistics
Customers & Revenue
This section describes hospital use of predictive AI, including 67% using predictive AI for scheduling in 2024 and 71% integrating predictive AI into EHRs.
Buyer penetration in the medical AI industry
- 67% of U.S. hospitals used predictive AI to facilitate scheduling in 2024, compared with 51% in 2023.[7]
- 61% of U.S. hospitals used predictive AI to simplify or automate billing in 2024, compared with 36% in 2023.[7]
- 71% of U.S. non-federal acute-care hospitals used predictive AI integrated into their EHRs in 2024; predictive AI was defined as statistical analysis or machine learning producing classifications or risk scores.[7]
06 Statistics
Pricing & Packaging
This section provides observed pricing context, including $29 per month or $180 per year for a Pro plan and a sample spanning free tiers to enterprise offerings without public rates.
Price levels in the medical AI industry
- Medical AI’s Pro plan costs $29 per month or $180 per year in the United States, implying a 48.3% discount for annual billing versus twelve monthly payments.[8]
- Among 42 clinical-AI tools observed on October 22, 2026, published prices ranged from free tiers to enterprise offerings with no public rate; the sample covered medical scribes, decision support, reasoning, coding, APIs and presentation tools.[9]
- Published individual subscription prices in the 2026 clinical-AI sample included $38 per month for EvidenceMD, about $119 per month for Nabla, and $89 per month for Commure Scribe.[9]
07 Statistics
Finance
This section quantifies investment patterns, including $3.2 billion raised by AI startups in Q1 2025 and $10.4 billion attracted by clinical-decision-support AI startups during 2010–2024.
Funding and investment in the medical AI industry
- AI startups raised $3.2 billion, representing 60% of digital-health funding in Q1 2025; the report’s AI scope includes clinical documentation, drug discovery and other healthcare applications.[10]
- AI-focused companies received 42% of digital-health funding and represented 31% of digital-health deals in 2024, according to CB Insights’ digital-health market scope.[10]
- $23 billion was raised in 1,387 healthcare startup venture rounds in 2024; Carta’s healthcare scope includes healthtech, biotech and pharmaceuticals, with AI-focused companies identified as a major investment area.[11]
- Clinical-decision-support AI startups attracted $10.4 billion during 2010–2024, while medical-monitoring AI startups attracted $6.78 billion; the study covers AI-health startups across ten medical domains.[12]
- $14.5 million was the median healthcare startup seed valuation in Q4 2024, while the Series A median was $37.4 million; the dataset includes AI-focused healthcare companies.[11]
08 Statistics
Security & Compliance
This section sets compliance constraints, including €15 million or 3% of worldwide annual turnover caps under EU AI Act Article 99 and the 2 August 2028 start for certain high-risk obligations.
Regulatory obligations in the medical AI industry
- EU AI Act Article 99 caps fines for provider obligations, including Article 16 obligations applicable to high-risk medical-AI providers, at €15 million or 3% of worldwide annual turnover, whichever is higher.[13]
- EU AI Act high-risk obligations for AI systems that are safety components of regulated medical products apply from 2 August 2028 under Article 113, covering qualifying medical-device AI in the European Union.[13]
- 1,524 AI-enabled medical devices were listed by the FDA as of June 2026, indicating the U.S. market population subject to FDA medical-device authorization pathways.[5]
09 Statistics
Sustainability
This section reports emissions comparisons, including 34% lower emissions from cloud-based APIs with carbon-aware load balancing than on-premise always-on infrastructure in a 2026 life-cycle assessment.
Energy use, emissions and disclosure in the medical AI industry
- 8-fold lower carbon emissions were reported on average by AI-in-radiology studies using sustainability comparisons, alongside similar or improved clinical performance; the review covers published studies rather than providers.[14]
- 34% lower emissions were achieved by cloud-based APIs with carbon-aware load balancing than on-premise always-on infrastructure in a 2026 life-cycle assessment of LLM healthcare documentation.[15]
- 28% of the energy cost of flagship models was required by distilled models in a 2026 life-cycle assessment of LLM-based healthcare documentation.[15]
Key questions about the medical AI industry
What is the current size of the medical AI market in 2026?
How fast is the medical AI market expected to grow after 2026?
Which companies lead the medical AI industry?
What technology shift is described for medical AI as it scales?
How is the FDA authorization landscape structured for AI-enabled medical devices?
What gap exists between clinical evidence and broader device adoption?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 20). Medical AI Industry Statistics. Gitnux. https://gitnux.org/medical-ai-industry-statistics
Samuel Norberg. "Medical AI Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/medical-ai-industry-statistics.
Samuel Norberg. 2026. "Medical AI Industry Statistics." Gitnux. https://gitnux.org/medical-ai-industry-statistics.
Sources & references
28 sources cited across this report
marketsandmarkets.com
reportsanddata.com
grandviewresearch.com
capstonepartners.com
fda.gov
jmir.org
healthit.gov
- medicalaiapp.com
- medicalaireport.com
cbinsights.com
carta.com
nature.com
eur-lex.europa.eu
bmjdigitalhealth.bmj.com
ssrn.com
hai.stanford.edu
doximity.com
menlovc.com
ama-assn.org
d3fbjrz68b519c.cloudfront.net
global.united-imaging.com
viz.ai
aidoc.com
axios.com
mordorintelligence.com
thebusinessresearchcompany.com
ir.butterflynetwork.com
pubmed.ncbi.nlm.nih.gov